False-positive HIV screening tests during the COVID-19 pandemic, a passing trend?


Journal

AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219

Informations de publication

Date de publication:
01 12 2023
Historique:
medline: 16 11 2023
pubmed: 15 11 2023
entrez: 15 11 2023
Statut: ppublish

Résumé

False-positive fourth-generation HIV screening tests are rare and are usually associated with various infections and autoimmune diseases. SARS-CoV-2 infection and vaccination were recently linked with false-positive HIV screening test results. However, little is known about false-positives in people who performed HIV screening tests after outbreaks of different SARS-CoV-2 strains and vaccination campaigns. Here, we examined the false-positive rates in samples collected by the Israeli AIDS Task Force in 2018--2022, with respect to such factors.

Identifiants

pubmed: 37965741
doi: 10.1097/QAD.0000000000003693
pii: 00002030-202312010-00021
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2430-2432

Informations de copyright

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Références

Corona Virus Registry, Israel Ministry of Health. https://www.gov.il/en/departments/topics/corona-main-sub/govil-landing-page. [Accessed 15 June 2023]
Ministry of Health, Public Health Services, Division of Epidemiology Department of Tuberculosis & AIDS, Jerusalem, Israel. HIV/AIDS in Israel: 1981–2021 Epidemiological Report. https://www.health.gov.il/PublicationsFiles/aids_periodicreport2022e.pdf. [Accessed 2 June 2023]
Deas JE, Liu LG, Thompson JJ, Sander DM, Soble SS, Garry RF, et al. Reactivity of sera from systemic lupus erythematosus and Sjögren's syndrome patients with peptides derived from human immunodeficiency virus p24 capsid antigen. Clin Diagn Lab Immunol 1998; 5:181–185.
Lee K, Park H-D, Kang E-S. Reduction of the HIV seroconversion window period and false positive rate by using ADVIA Centaur HIV antigen/antibody combo assay. Ann Lab Med 2013; 33:420–425.
Shida S, Takahashi N, Fujishima N, Kameoka Y, Nara M, Fujishima M, et al. False-positive human immunodeficiency virus antibody test and autoimmune hemolytic anemia in a patient with angioimmunoblastic T-cell lymphoma. Intern Med 2011; 50:2383–2387.
Everett DB, Baisely KJ, McNerney R, Hambleton I, Chirwa T, Ross DA, et al. Association of schistosomiasis with false-positive HIV test results in an African adolescent population. J Clin Microbiol 2010; 48:1570–1577.
Hakobyan N, Yadav R, Abaza K, Friedman A. False-positive human immunodeficiency virus results in COVID-19 patients. Cureus 2023; 15:e34096.
Alfie LG, Longueira YS, Pippo M, Cruces L, Quiroga MF, Turk G, et al. Increased risk of false positive HIV ELISA results after COVID-19. AIDS 2023; 37:947.
Modesto-dos-Santos V, Modesto-Sugai TA. False-positive HIV results and COVID-19 infection or vaccination?. Microbes Infect Chemother 2023; 17:e1832.
The ARCHITECT HIV Ag/Ab Combo assay. https://www.fda.gov/media/116836/download. [Accessed 10 June 2023]
HIV Ag/Ab Combo, Abbott Diagnostic Division, Germany. https://www.ilexmedical.com/files/PDF/HIVAgAbCombo.pdf. [Accessed 10 June 2023]
Lin Y-Q, Gao Y-L, Wang M, Yan S-D, Lin L-R. Analysis of the characteristics of patients with false-positive HIV screening assay results. Int Immunopharmacol 2022; 105:108556.
Chacón L, Mateos ML, Holguín Á. Relevance of cutoff on a 4th generation ELISA performance in the false positive rate during HIV diagnostic in a low HIV prevalence setting. J Clin Virol 2017; 92:11–13.
Hossain A, Akter S, Rashid AA, Khair S, Alam ASMRU. Unique mutations in SARS-CoV-2 Omicron subvariants’ nonspike proteins: potential impacts on viral pathogenesis and host immune evasion. Microb Pathog 2022; 170:105699.
Solanki K, Rajpoot S, Kumar A, Zhang KY, Ohishi T, Hirani N, et al. Structural analysis of spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations. Future Virol 2022; 10:723–732.
Amar S, Avni YS, O’Rourke N, Michael T. Prevalence of common infectious diseases after COVID-19 vaccination and easing of pandemic restrictions in Israel. JAMA Netw Open 2022; 5:e2146175.

Auteurs

Rinat Lasmanovich (R)

Israel AIDS Task Force.

Dor Atias (D)

Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicine, Tel Aviv University, Tel Aviv.

Orna Mor (O)

Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicine, Tel Aviv University, Tel Aviv.
Central Virology Laboratory, Ministry of Health, Sheba Medical Center, Ramat-Gan.

Uri Obolski (U)

Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicine, Tel Aviv University, Tel Aviv.
Porter School of the Environment and Earth Sciences, Faculty of Exact Sciences, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH